Cordlife (SGX:P8A) expects to book a loss for the year ended Dec. 31, 2024, according to a filing with the Singapore Exchange on Tuesday.
The company has attributed this to suspension of Singapore operations and ban on collection, testing, processing of new cord blood and human tissues and conditional resumption of operatins in a controlled manner.
The company expects revenue to improve during 2025 and will release its financial results on or before March 1.